Maven Bio provides an AI‑powered platform that automatically gathers, structures, and cites primary biopharma data from clinical trials, regulatory filings, and market sources. The system delivers real‑time insights, Smart Tables, and citation‑rich reports that enable pharma, biotech, consulting, and investment teams to conduct deep, evidence‑backed analyses at scale.
Funding
$500K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Pharma, biotech, consulting, and investment teams spend extensive time manually gathering and synthesizing primary-source data on clinical trials, regulatory filings, and market activity, which limits the speed, depth, and defensibility of their strategic analyses.
Solution
Maven Bio offers an AI‑powered platform that automates the collection, structuring, and citation of primary biopharma data across clinical, regulatory, scientific, and corporate sources. Users define a research request, approve a generated analytical plan, and receive structured outputs such as Smart Tables, Report Builder documents, and Watchlist alerts, all linked to verifiable source material. The system continuously monitors global trial registries, regulatory agencies, stock exchanges, and news feeds, delivering real‑time insights on competitor pipelines, market shifts, and regulatory events. By encoding firm‑specific evaluation frameworks, Maven Bio ensures consistent, repeatable analysis that scales across teams while preserving the depth required for board‑level and investor presentations.
Target Audience
Primary customers are pharmaceutical and biotech strategic teams, life‑science consulting firms, and investment organizations (venture, private equity, investment banking, and public‑market analysts) that require rapid, evidence‑backed market and pipeline intelligence.
Features
- AI‑driven “Research Agent” that executes analyst‑level screening, evidence gathering, and report generation on demand
- Smart Tables that apply a user‑defined analytical framework uniformly across hundreds of assets, trials, and competitors
- Report Builder creates citation‑rich, structured research reports with average 105 vetted sources per document
- Watchlists provide contextual, source‑backed alerts on 320 K+ tracked items and 250+ daily market events
- Continuous coverage of 21 trial registries, 79 stock exchanges, 109 countries, and major regulatory bodies (FDA, EMA, SEC)
- Enterprise‑grade security (SOC II, AES‑256 at rest, TLS 1.3, SSO/SAML) and optional private‑data sync